Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RVB-003
- Development stage
- Preclinical
- Lead developer
- ResVita Bio
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
RVB-003 is a genetically engineered protein therapeutic developed by ResVita Bio for the treatment of Netherton syndrome, a rare and life-threatening genetic skin disorder. The drug utilizes a novel continuous protein therapy platform that employs genetically engineered probiotic bacteria applied topically to the skin. These bacteria temporarily colonize the skin and continuously release therapeutic proteins—specifically LEKTI (a serine protease inhibitor)—to restore the integrity of the skin barrier by inhibiting uncontrolled protease activity caused by SPINK5 gene mutations. This approach aims to provide sustained delivery of therapy directly at the site of disease, potentially offering improved safety and efficacy over traditional treatments. RVB-003 has received orphan drug designation and rare pediatric disease designation from the FDA for Netherton syndrome[1][2][3][4][5][7].
02
Targets
KLK5 (Kallikrein-related peptidase 5)KLK7
Beyond the preview
Go deeper on RVB-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RVB-003.